Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure

The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Participants currently hospitalized for acute decompensated heart failure (ADHF)
• Participants must be hemodynamically stable, as assessed by the investigator
• Men must agree to follow specific methods of contraception, if applicable, while participating in the trial
• Women participants must have documented proof that they are not of childbearing potential

Exclusion Criteria:

• Acute cardiovascular condition other than heart failure (HF) decompensation
• Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization
• Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization
• Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis

Other protocol-defined inclusion/exclusion criteria apply